SCHEMBL1139999

SCHEMBL1139999

C=C(C)COc1ccc2ncn(-c3cc(C(=O)NC4CC4)ccc3C)c(=O)c2c1

nearest known ligand 0.63

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 20/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1140702 0.89 MAPK14 (0.62) MAPK14
SCHEMBL1140413 0.88 MAPK14 (0.65) MAPK14
SCHEMBL1140091 0.88 MAPK14 (0.65) MAPK14
SCHEMBL1140549 0.88 MAPK14 (0.69) MAPK14
SCHEMBL1140617 0.87 MAPK14 (0.62) MAPK14
SCHEMBL1139878 0.87 MAPK14 (0.64) MAPK14
SCHEMBL1140083 0.87 MAPK14 (0.64) MAPK14
SCHEMBL1140368 0.86 MAPK14 (0.63) MAPK14
SCHEMBL1140024 0.86 MAPK14 (0.62) MAPK14
SCHEMBL1139969 0.85 MAPK14 (0.62) MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1682520-B1 AMIDE DERIVATIVES ASTRAZENECA AB (SE) 2011-02-23 EP disclosed
US-7750154-B2 Amide derivatives ASTRAZENECA AB (SE) 2010-07-06 US disclosed
US-20070043065-A1 Amide derivatives ASTRAZENECA AB (SE) 2007-02-22 US disclosed
EP-1682520-A1 AMIDE DERIVATIVES AstraZeneca AB (SE) 2006-07-26 EP disclosed
WO-2005042502-A1 AMIDE DERIVATIVES ASTRAZENECA AB (SE) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043065-A1 Amide derivatives IL6, IL2, IL1B MAPK14 2518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.